Non-Steroidal Nasal Sprays with no adverse effects for Treatment of Respiratory Diseases, COVID-19, Long COVID, Flu, and more.

PRESS RELEASES

To read and or download the pdf articles click on the links below.

 

• October 5, 2021 – EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis

---

• December 1 2020 – Sodium Pyruvate Ameliorates Influenza A Virus Infection In Vivo _ Peer Review bioRxiv

---

• April 7, 2020  – EmphyCorp N115 News: Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide

---

• March 24, 2020 – EmphyCorp News: As Reported in The Lancet – Clinical Features of Patients Infected with the 2019 novel Coronavirus in Wuhan, China

---

• March 17, 2020  – EmphyCorp News: Nitric Oxide is currently being tested in Clinical Trials as a Potential Treatment for Patients infected with the Coronavirus

---

• January 21, 2020 – EmphyCorp N115 Rx Globally Patented Non-Steroidal Nasal Spray with No Known Side Effects for Pregnant Women with Allergic Rhinitis or Asthma

---

• January 14, 2020 – Rx Globally Patented Non-Steroidal Nasal Spray for All Lung Diseases including Pulmonary Fibrosis, CF, COPD, Unmet Needs with No Known Side Effects that can also be used to Deliver Antivirals, Antimicrobials, Insulin, and other Drugs

---

• August 15, 2019 – EmphyCorp Inc. FDA Submission for Rx New Non-Steroidal Nasal Spray for Pulmonary Fibrosis w/ No Known Side Effects